MedPath

FLuorescence Cholangiography Using Methylene Blue

Not Applicable
Conditions
Bile Duct Injury
Interventions
Drug: Intravenous Methylene blue
Registration Number
NCT03386201
Lead Sponsor
University of Oxford
Brief Summary

Open label prospective, non-randomised proof of principle study assessing the use of methylene blue fluorescence cholangiography.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Participant is willing and able to give informed consent for participation in the study.
  • Male or Female, aged 18 years or above.
  • Undergoing laparoscopic cholecystectomy
Read More
Exclusion Criteria
  • Patient who is unable or unwilling to give informed consent
  • Known allergy to methylene blue
  • Risk of serotonin syndrome (taking SSRI / G6PD deficiency / previous serotonin syndrome)
  • Significant renal failure
  • Pregnant / planning pregnancy or breastfeeding
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Intravenous methylene blueIntravenous Methylene blue-
Primary Outcome Measures
NameTimeMethod
Concordance of surgeon anatomy definition with fluorescence outlineIntraoperative (At end of laparoscopic cholecystectomy)
Secondary Outcome Measures
NameTimeMethod
Signal to background ratio over time throughout laparoscopic cholecystectomy0, 10, 20, 30, 40, 50, 60, minutes and at 10 minute intervals thereafter post injection of methylene blue

Trial Locations

Locations (1)

Oxford University Hospitals NHS Foundation Trust

🇬🇧

Oxford, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath